Abeona Therapeutics (ABEO)

[stockguard]

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday, December 30th, MarketBeat.com reports. They presently have a $11.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. HC Wainwright’s price objective would suggest a potential upside of 366.10% from the company’s current price.

Other research analysts have also recently issued research reports about the company. ValuEngine raised Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald started coverage on shares of Abeona Therapeutics in a research note on Tuesday, December 10th. They set a “hold” rating and a $4.00 price objective on the stock. Zacks Investment Research lowered shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. Finally, Mizuho reaffirmed a “hold” rating and issued a $4.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Abeona Therapeutics presently has a consensus rating of “Hold” and an average target price of $7.50.

Shares of NASDAQ ABEO opened at $2.36 on Monday. Abeona Therapeutics has a 12-month low of $1.46 and a 12-month high of $8.41. The company has a current ratio of 2.45, a quick ratio of 2.45 and a debt-to-equity ratio of 0.07. The company has a market cap of $129.15 million, a price-to-earnings ratio of -1.98 and a beta of 2.13. The stock’s 50 day simple moving average is $3.26 and its 200 day simple moving average is $2.93.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.09. As a group, equities analysts forecast that Abeona Therapeutics will post -1.52 earnings per share for the current fiscal year.

In other Abeona Therapeutics news, Director Stefano Buono bought 200,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were bought at an average price of $2.50 per share, for a total transaction of $500,000.00. Following the acquisition, the director now directly owns 270,000 shares of the company’s stock, valued at $675,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 33.60% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its position in Abeona Therapeutics by 434.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 7,088 shares in the last quarter. Ellington Management Group LLC acquired a new position in shares of Abeona Therapeutics during the second quarter worth approximately $50,000. Trexquant Investment LP bought a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $53,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter worth $59,000. Finally, Marshall Wace LLP increased its position in Abeona Therapeutics by 45.9% during the second quarter. Marshall Wace LLP now owns 13,254 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 4,168 shares during the period. Institutional investors and hedge funds own 55.85% of the company’s stock.
About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.



https://rivertonroll.com/news/2020/01/14/abeona-therapeutics-nasdaqabeo-price-target-increased-to-15-00-by-analysts-at-hc-wainwright-updated-updated.html